Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Lorlatinib Continuation Study
Lorlatinib Continuation Study

NCT05144997

Active Not RecruitingPhase 4

Sponsor: Pfizer

Conditions: Non-Small-Cell Lung Cancer, NSCLC

Interventions: Lorlatinib

Countries: United States, China, France, India, Japan, Singapore, Spain, Taiwan

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study.

2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function

Exclusion Criteria:

1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
Locations (27)
  • Irvine, California, United States
  • Hefei, Anhui, China
  • Beijing, Beijing Municipality, China
  • Beijing, Beijing Municipality, China
  • Fuzhou, Fujian, China
  • Guangzhou, Guangdong, China
  • Changsha, Hunan, China
  • Nanjing, Jiangsu, China
  • Changchun, Jilin, China
  • Changchun, Jilin, China
  • Hangzhou, Qiantang District, China
  • Xi'an, Shaanxi, China
  • Shanghai, Shanghai Municipality, China
  • Chengdu, Sichuan, China
  • Hangzhou, Zhejiang, China
  • Hangzhou, Zhejiang, China
  • Hangzhou, Zhejiang, China
  • Shanghai, China
  • Rennes, France
  • Villejuif, France
  • Bengaluru, Karnataka, India
  • Thane, Maharashtra, India
  • Nagoya, Aichi-ken, Japan
  • Singapore, Singapore
  • Singapore, Singapore
  • Barcelona, Spain
  • Taipei, Taiwan